BidaskClub downgraded shares of Catalyst Pharmaceuticals (NASDAQ:CPRX) from a buy rating to a hold rating in a report released on Saturday.
Several other research firms have also recently weighed in on CPRX. Piper Jaffray Companies set a $8.00 price objective on Catalyst Pharmaceuticals and gave the company a buy rating in a research report on Friday, December 1st. SunTrust Banks reiterated a buy rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Wednesday, November 29th. HC Wainwright restated a buy rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research note on Thursday, December 21st. Zacks Investment Research lowered Catalyst Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, November 14th. Finally, Roth Capital set a $5.00 target price on Catalyst Pharmaceuticals and gave the company a buy rating in a research note on Wednesday, November 1st. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $6.25.
Catalyst Pharmaceuticals (NASDAQ:CPRX) remained flat at $$3.95 on Friday. 496,034 shares of the company traded hands, compared to its average volume of 1,640,000. Catalyst Pharmaceuticals has a twelve month low of $1.03 and a twelve month high of $4.51. The company has a market capitalization of $340.31, a P/E ratio of -18.81 and a beta of 1.68.
Several large investors have recently added to or reduced their stakes in the company. Nationwide Fund Advisors acquired a new stake in Catalyst Pharmaceuticals in the 2nd quarter valued at approximately $111,000. New York State Common Retirement Fund acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $114,000. SG Americas Securities LLC acquired a new position in shares of Catalyst Pharmaceuticals during the 3rd quarter worth approximately $144,000. State of Wisconsin Investment Board acquired a new position in shares of Catalyst Pharmaceuticals during the 2nd quarter worth approximately $149,000. Finally, The Manufacturers Life Insurance Company increased its position in shares of Catalyst Pharmaceuticals by 1,861.3% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 63,114 shares of the biopharmaceutical company’s stock worth $175,000 after purchasing an additional 59,896 shares during the last quarter. Institutional investors and hedge funds own 34.75% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This article was published by Equities Focus and is the property of of Equities Focus. If you are accessing this article on another site, it was illegally copied and republished in violation of US & international copyright & trademark legislation. The original version of this article can be viewed at https://www.equitiesfocus.com/2018/01/08/catalyst-pharmaceuticals-cprx-lowered-to-hold-at-bidaskclub.html.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.